Tim-3 expression in renal cell carcinoma is associated with longer progression-free survival and OS (51), whereas low Tim-3 expression levels in tumor tissue is associated with poor prognosis in metastatic prostate cancer (52). This evidence concerns the gene HAVCR2 and metastatic prostate carcinoma.